Humanigen, Inc. Receives Preliminary Topline Data from NIH/N

Humanigen, Inc. has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases' ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus... | July 13, 2022

Related Keywords

, National Institutes Of Health , Humanigen Inc , National Institute Of Allergy , National Institute , Infectious Disease , National Institutes , Big Effect Trial , Humanigen , Nc Stock Exchange , News , Information , Press Release , Gas , Teen , Nformed , F , Reliminary , Topline , Results , Rom , The , Ational , Institute , Allergy , End , Nfectious , Trial , Valuating , Lenzilumab , Plus , Emdesivir Hgen Us4448632038 ,